Clinigen facilitates treatments by their 5,000 member hospitals through a 'named patient' authorization. In France, we have the opportunity to sell product on a 'named cohort' basis. These authorizations allow the company to collect revenue for these treatments.
I did love buying this stock at sub-$2.00, and I have already done that at about $1.89. I'll scale in again if price drops to <$0.99. There's significant short interest in this stock, and if they continue to drive price down, I'll add.
News 
Market Data 
Discover 
